The recent fatalities linked to Sarepta’s gene therapies evoke parallels with the historic Jesse Gelsinger case, reigniting scrutiny of safety in AAV-mediated treatments. Industry experts and FDA officials emphasize the urgent need for collaborative efforts to analyze these tragic outcomes and refine gene therapy protocols. Both editorials and patient advocacy highlight the imperative of balancing innovation with stringent safety oversight to protect vulnerable populations and sustain public trust.